Challenges faced in clinical trials for chronic allergic conjunctivitis

References

• Abelson MB, Shetty S, Korchak M, et al. Advances in pharmacotherapy for allergic conjunctivitis. Expert Opin Pharmacother 2015;16(8):1219-31
   PubMed Web of Science ®Google Scholar
• Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115(1):118-22
   PubMed Web of Science ®Google Scholar
• Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 2010;126(4):778-783 e6
   PubMed Web of Science ®Google Scholar
• Broide DH. The pathophysiology of allergic rhinoconjunctivitis. Allergy Asthma Proc 2007;28(4):398-403
   PubMed Web of Science ®Google Scholar
• Kari O, Saari KM. Updates in the treatment of ocular allergies. J Asthma Allergy 2010;3:149-58
   Google Scholar
• Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin North Am 2005;18(4):485-92
   PubMedGoogle Scholar
• Li Z, Mu G, Chen W, et al. Comparative evaluation of topical pranoprofen and fluorometholone in cases with chronic allergic conjunctivitis. Cornea 2013;32(5):579-82
   PubMed Web of Science ®Google Scholar
• Mishra GP, Tamboli V, Jwala J, et al. Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov 2011;5(1):26-36
   PubMedGoogle Scholar
• O’Brien TP. Allergic conjunctivitis: an update on diagnosis and management. Curr Opin Allergy Clin Immunol 2013;13(5):543-9
   PubMed Web of Science ®Google Scholar
• Alexander M, Berger W, Buchholz P, et al. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ). Health Qual Life Outcomes 2005;3:67
   PubMedGoogle Scholar
• Bielory BP, O’Brien TP, Bielory L. Management of seasonal allergic conjunctivitis: guide to therapy. Acta Ophthalmol 2012;90(5):399-407
   PubMed Web of Science ®Google Scholar
• Gomes PJ. Trends in prevalence and treatment of ocular allergy. Curr Opin Allergy Clin Immunol 2014;14(5):451-6
   PubMed Web of Science ®Google Scholar
• Chambless SL, Trocme S. Developments in ocular allergy. Curr Opin Allergy Clin Immunol 2004;4(5):431-4
   PubMedGoogle Scholar
• Guarnieri M, Balmes JR. Outdoor air pollution and asthma. Lancet 2014;383(9928):1581-92
   PubMed Web of Science ®Google Scholar
• Fujishima H, Satake Y, Okada N, et al. Effects of diesel exhaust particles on primary cultured healthy human conjunctival epithelium. Ann Allergy Asthma Immunol 2013;110(1):39-43
   PubMed Web of Science ®Google Scholar
• Brandt EB, Kovacic MB, Lee GB, et al. Diesel exhaust particle induction of IL-17A contributes to severe asthma. J Allergy Clin Immunol 2013;132(5):1194-1204 e2
   PubMed Web of Science ®Google Scholar
• Leonardi A, Lanier B. Urban eye allergy syndrome: a new clinical entity? Curr Med Res Opin 2008;24(8):2295-302
   PubMed Web of Science ®Google Scholar
• Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 2004;30(1):10-13
   PubMedGoogle Scholar
• Gomes P, Abelson MB, Mandell K. Perennial allergen skin sensitivity as a predictor of seasonal allergic rhinoconjunctivitis severity. J Allerg Clin Immunol 2010;125(2):AB172
   Google Scholar
• Baiula M, Spampinato S. Mapracorat, a novel non-steroidal selective glucocorticoid receptor agonist for the treatment of allergic conjunctivitis. Inflamm Allergy Drug Targets 2014;13(5):289-98
   PubMedGoogle Scholar
• Ousler GW, Gomes PJ, Welch D, et al. Methodologies for the study of ocular surface disease. Ocul Surf 2005;3(3):143-54
   PubMed Web of Science ®Google Scholar
• McGill JI, Holgate ST, Church MK, et al. Allergic eye disease mechanisms. Br J Ophthalmol 1998;82(10):1203-14
   PubMed Web of Science ®Google Scholar
• Dartt DA, Masli S. Conjunctival epithelial and goblet cell function in chronic inflammation and ocular allergic inflammation. Curr Opin Allergy Clin Immunol 2014;14(5):464-70
   PubMed Web of Science ®Google Scholar
• Baiula M, Bedini A, Carbonari G, et al. Therapeutic targeting of eosinophil adhesion and accumulation in allergic conjunctivitis. Front Pharmacol 2012;3:203
   Google Scholar
• Bacon AS, Ahluwalia P, Irani AM, et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J Allergy Clin Immunol 2000;106(5):948-54
   PubMed Web of Science ®Google Scholar
• Leonardi A. Allergy and allergic mediators in tears. Exp Eye Res 2013;117:106-17
   PubMed Web of Science ®Google Scholar
• Leonardi A. Pathophysiology of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999(228):21-3
   PubMedGoogle Scholar
• Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990;108(1):84-8
   PubMed Web of Science ®Google Scholar
• Badorrek P, Dick M, Hecker H, et al. Anti-allergic drug testing in an environmental challenge chamber is suitable both in and out of the relevant pollen season. Ann Allergy Asthma Immunol 2011;106(4):336-41
   PubMed Web of Science ®Google Scholar
• Mantelli F, Lambiase A, Bonini S, et al. Clinical trials in allergic conjunctivits: a systematic review. Allergy 2011;66(7):919-24
   PubMed Web of Science ®Google Scholar
• Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol 2015;135(6):1494-501
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Tubridy KL, Agahigian J, et al. A Phase II exploratory study of a novel interleukin-1 receptor inhibitor (EBI-005) in the treatment of moderate-to-severe allergic conjunctivitis. Eye Contact Lens 2015;41(3):145-55
   PubMed Web of Science ®Google Scholar
• Akerlund A, Andersson M, Leflein J, et al. Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication. J Allergy Clin Immunol 2005;115(3 Suppl 1):S460-82
   PubMedGoogle Scholar
• Yasuda M, Kato M, Nabe T, et al. An experimental allergic conjunctivitis induced by topical and repetitive applications of Japanese cedar pollens in guinea pigs. Inflamm Res 1999;48(6):325-36
   PubMed Web of Science ®Google Scholar
• Fukushima Y, Nabe T, Mizutani N, et al. Multiple cedar pollen challenge diminishes involvement of histamine in allergic conjunctivitis of Guinea pigs. Biol Pharm Bull 2003;26(12):1696-700
   PubMed Web of Science ®Google Scholar
• Katayama G, Nabe T, Fujii M, et al. Mast cell hyperplasia induced by multiple challenge with cedar pollen in sensitised guinea pigs. Inflamm Res 2005;54(9):370-4
   PubMed Web of Science ®Google Scholar
• Nagata T, Nabe T, Fujii M, et al. Effects of multiple dexamethasone treatments on aggravation of allergic conjunctivitis associated with mast cell hyperplasia. Biol Pharm Bull 2008;31(3):464-8
   PubMed Web of Science ®Google Scholar
• Gomes P, Abelson MB, Edwards M, et al. An evaluation of olopatadine 0.2% opthalmic solution in the modified conjunctival allergen challenge (CAC) model. Ann Allergy Asthma Immunol 2009
   Web of Science ®Google Scholar
• Gomes PJ, Yunes S, Welch D, Ableson MB. Evaluation of the effect of multiple doses of PredForte (prednisolone acetate 1%) in the prevention of conjunctival allergen challenge-induced ocualr allergic signs and symptoms. Invest Opthalmol 2006;47:13
   Google Scholar
• Singh R, et al. Impression cytology of the ocular surface. Br J Ophthalmol 2005;89(12):1655-9
   PubMed Web of Science ®Google Scholar
• Sanchez BM, Lesch M, Brammer D, et al. Use of a portable thermal imaging unit as a rapid, quantitative method of evaluating inflammation and experimental arthritis. J Pharmacol Toxicol Methods 2008;57(3):169-75
   PubMedGoogle Scholar
• Klamann MK, Maier AK, Gonnermann J, et al. Thermography: a new option to monitor filtering bleb function? J Glaucoma 2015;24(4):272-7
   PubMed Web of Science ®Google Scholar
• Efron N, Brennan NA, Hore J, et al. Temperature of the hyperemic bulbar conjunctiva. Curr Eye Res 1988;7(6):615-18
   PubMed Web of Science ®Google Scholar
• Hara Y, Shiraishi A, Yamaguchi M, et al. Evaluation of allergic conjunctivitis by thermography. Ophthalmic Res 2014;51(3):161-6
   PubMed Web of Science ®Google Scholar
• Efron N, Al-Dossari M, Pritchard N. In vivo confocal microscopy of the bulbar conjunctiva. Clin Experiment Ophthalmol 2009;37(4):335-44
   PubMed Web of Science ®Google Scholar
• Villani E, Mantelli F, Nucci P. In-vivo confocal microscopy of the ocular surface: ocular allergy and dry eye. Curr Opin Allergy Clin Immunol 2013;13(5):569-76
   PubMed Web of Science ®Google Scholar
• Enriquez-de-Salamanca A, Bonini S, Calonge M. Molecular and cellular biomarkers in dry eye disease and ocular allergy. Curr Opin Allergy Clin Immunol 2012;12(5):523-33
   PubMed Web of Science ®Google Scholar
• Mantelli F, Calder VL, Bonini S. The anti-inflammatory effects of therapies for ocular allergy. J Ocul Pharmacol Ther 2013;29(9):786-93
   PubMed Web of Science ®Google Scholar
• Gomes PJ, Ousler GW, Welch DL, et al. Exacerbation of signs and symptoms of allergic conjunctivitis by a controlled adverse environment challenge in subjects with a history of dry eye and ocular allergy. Clin Ophthalmol 2013;7:157-65
   PubMedGoogle Scholar
• Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye (Lond) 2006;20(4):407-16
   PubMed Web of Science ®Google Scholar
• Carnahan M C, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000;11(6):478-83
   PubMedGoogle Scholar
• Cutolo M, Seriolo B, Pizzorni C, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev 2008;8(2):153-5
   PubMed Web of Science ®Google Scholar
• Pacharn P, Vichyanond P. Immunomodulators for conjunctivitis. Curr Opin Allergy Clin Immunol 2013;13(5):550-7
   PubMed Web of Science ®Google Scholar
• Wan XC, Dimov V. Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis. Expert Opin Drug Metab Toxicol 2014;10(4):543-9
   PubMed Web of Science ®Google Scholar
• Shii D, Nakagawa S, Yoshimi M, et al. Inhibitory effects of cyclosporine a eye drops on symptoms in late phase and delayed-type reactions in allergic conjunctivitis models. Biol Pharm Bull 2010;33(8):1314-18
   PubMed Web of Science ®Google Scholar
• Fukushima A, Yamaguchi T, Ishida W, et al. Cyclosporin A inhibits eosinophilic infiltration into the conjunctiva mediated by type IV allergic reactions. Clin Experiment Ophthalmol 2006;34(4):347-53
   PubMed Web of Science ®Google Scholar
• Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology 1998;105(9):1715-20
   PubMed Web of Science ®Google Scholar
• Kiiski V, Remitz A, Reitamo S, et al. Long-term safety of topical pimecrolimus and topical tacrolimus in atopic blepharoconjunctivitis. JAMA Dermatol 2014;150(5):571-3
   PubMed Web of Science ®Google Scholar
• Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther 2010;26(2):165-74
   PubMed Web of Science ®Google Scholar
• Ryu EH, Kim JM, Laddha PM, et al. Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis. Korean J Ophthalmol 2012;26(4):241-7
   PubMedGoogle Scholar
• Double-masked trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) versus vehicle in pediatric patients with active severe vernal keratoconjunctivitis. Available from: https://clinicaltrials.gov/ct2/show/NCT01751126?term=cyclosporine+vernal+keratoconjunctivitis&rank=1
   Google Scholar
• Topical tacrolimus in vernal keratoconjunctivitis. Available from: https://clinicaltrials.gov/ct2/show/NCT02456025?term=NCT02456025&rank=1
   Google Scholar
• Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep 2011;11(3):205-11
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Jia Y, Domenico J, et al. Sequential engagement of FcepsilonRI on Mast Cells and Basophil Histamine H(4) Receptor and FcepsilonRI in Allergic Rhinitis. J Immunol 2013;190(2):539-48
   PubMed Web of Science ®Google Scholar
• Saban DR, Calder V, Kuo CH, et al. New twists to an old story: novel concepts in the pathogenesis of allergic eye disease. Curr Eye Res 2013;38(3):317-30
   PubMed Web of Science ®Google Scholar
• Kumagai N, Fukuda K, Fujitsu Y, et al. Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis. Prog Retin Eye Res 2006;25(2):165-87
   PubMed Web of Science ®Google Scholar
• Leonardi A. The central role of conjunctival mast cells in the pathogenesis of ocular allergy. Curr Allergy Asthma Rep 2002;2(4):325-31
   PubMedGoogle Scholar
• Leonardi A, Di Stefano A, Vicari C, et al. Histamine H4 receptors in normal conjunctiva and in vernal keratoconjunctivitis. Allergy 2011;66(10):1360-6
   PubMed Web of Science ®Google Scholar
• Liu C, Ma X, Jiang X, et al. Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol 2001;59(3):420-6
   PubMed Web of Science ®Google Scholar
• O’Reilly M, Alpert R, Jenkinson S, et al. Identification of a histamine H4 receptor on human eosinophils-role in eosinophil chemotaxis. J Recept Signal Transduct Res 2002 22(1-4):431-48
   Google Scholar
• Godthelp T, Holm AF, Fokkens WJ, et al. Dynamics of nasal eosinophils in response to a nonnatural allergen challenge in patients with allergic rhinitis and control subjects: a biopsy and brush study. J Allergy Clin Immunol 1996;97(3):800-11
   PubMed Web of Science ®Google Scholar
• Qasem AR, Bucolo C, Baiula M, et al. Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol 2008;76(6):751-62
   PubMed Web of Science ®Google Scholar
• Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Des Devel Ther 2011;5:77-84
   PubMed Web of Science ®Google Scholar
• Ackerman S, D’Ambrosio FJr, Greiner JV, et al. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. J Asthma Allergy 2013;6:43-52
   PubMedGoogle Scholar
• McLaurin EB, Marsico NP, Ackerman SL, et al. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther 2014;31(10):1059-71
   PubMed Web of Science ®Google Scholar
• De Bosscher K. Selective Glucocorticoid Receptor modulators. J Steroid Biochem Mol Biol 2010;120(2-3):96-104
   PubMed Web of Science ®Google Scholar
• Lowenberg M, Stahn C, Hommes DW, et al. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids 2008;73(9-10):1025-9
   PubMed Web of Science ®Google Scholar
• Stahn C, Löwenberg M, Hommes DW, et al. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007;275(1-2):71-8
   PubMed Web of Science ®Google Scholar
• Kato M, Hagiwara Y, Oda T, et al. Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases. J Ocul Pharmacol Ther 2011;27(4):353-60
   PubMed Web of Science ®Google Scholar
• Evans RM. Molecular characterization of the glucocorticoid receptor. Recent Prog Horm Res 1989;45:1-22; discussion 22-7
   PubMedGoogle Scholar
• Cavet ME, Volhejn S, Harrington KL, et al. Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells. Mol Vis 2013;19:1515-25
   PubMed Web of Science ®Google Scholar
• BusinessWire. Ocular therapeutics begins enrollment in phase 3 clinical trial for DEXTENZA for the treatment of allergic conjunctivitis 2015. Available from: www.businesswire.com/news/home/20150616005503/en/#.VYG4iflVhBc [Last accessad 16 June 2015]
   Google Scholar
• Hsu NM, Reisacher WR. A comparison of attrition rates in patients undergoing sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol 2012;2(4):280-4
   PubMed Web of Science ®Google Scholar
• Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014;7(1):6
   PubMedGoogle Scholar
• Redfern RL, McDermott AM. Toll-like receptors in ocular surface disease. Exp Eye Res 2010;90(6):679-87
   PubMed Web of Science ®Google Scholar
• Ueta M, Kinoshita S. Ocular surface inflammation is regulated by innate immunity. Prog Retin Eye Res 2012;31(6):551-75
   PubMed Web of Science ®Google Scholar
• Ulanova M, Duta F, Puttagunta L, et al. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opin Ther Targets 2005;9(5):901-21
   PubMed Web of Science ®Google Scholar
• Coffey G, DeGuzman F, Inagaki M, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther 2012;340(2):350-9
   PubMed Web of Science ®Google Scholar